Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2010

Open Access 01-12-2010 | Research article

Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity

Authors: Choong-Gu Lee, Ho-Keun Kwon, Jae Ha Ryu, Sung Jin Kang, Chang-Rok Im, Jae II Kim, Sin-Hyeog Im

Published in: BMC Complementary Medicine and Therapies | Issue 1/2010

Login to get access

Abstract

Background

Abalone has long been used as a valuable food source in East Asian countries. Although the nutritional importance of abalone has been reported through in vitro and in vivo studies, there is little evidence about the potential anti-tumor effects of abalone visceral extract. The aim of the present study is to examine anti-tumor efficacy of abalone visceral extract and to elucidate its working mechanism.

Methods

In the present study, we used breast cancer model using BALB/c mouse-derived 4T1 mammary carcinoma and investigated the effect of abalone visceral extract on tumor development. Inhibitory effect against tumor metastasis was assessed by histopathology of lungs. Cox-2 productions by primary and secondary tumor were measured by real-time RT-PCR and immunoblotting (IB). Proliferation assay based on [3H]-thymidine incorporation and measurement of cytokines and effector molecules by RT-PCR were used to confirm tumor suppression efficacy of abalone visceral extract by modulating cytolytic CD8+ T cells. The cytotoxicity of CD8+ T cell was compared by JAM test.

Results

Oral administration of abalone visceral extract reduced tumor growth (tumor volume and weight) and showed reduced metastasis as confirmed by decreased level of splenomegaly (spleen size and weight) and histological analysis of the lung metastasis (gross analysis and histological staining). Reduced expression of Cox-2 (mRNA and protein) from primary tumor and metastasized lung was also detected. In addition, treatment of abalone visceral extract increased anti-tumor activities of CD8+ T cells by increasing the proliferation capacity and their cytolytic activity.

Conclusions

Our results suggest that abalone visceral extract has anti-tumor effects by suppressing tumor growth and lung metastasis through decreasing Cox-2 expression level as well as promoting proliferation and cytolytic function of CD8+ T cells.
Appendix
Available only for authorised users
Literature
1.
2.
Hwang E, Baek J, Park C: The mass cultivation of Ecklonia stolonifera Okamura as a summer feed for the abalone industry in Korea. Journal of Applied Phycology. 2009
3.
Smit AJ: Medicinal and pharmaceutical uses of seaweed natural products: A review. Journal of Applied Phycology. 2004, 16 (4): 245-262. 10.1023/B:JAPH.0000047783.36600.ef.CrossRef
4.
Zhu B-W, Wang L-S, Zhou D-Y, Li D-M, Sun L-M, Yang J-F, Wu H-T, Zhou X-Q, Tada M: Antioxidant activity of sulphated polysaccharide conjugates from abalone (Haliotis discus hannai Ino). European Food Research and Technology. 2008, 227 (6): 1663-1668. 10.1007/s00217-008-0890-2.CrossRef
5.
Kim HL, Kang SG, Kim IC, Kim SJ, Kim DW, Ma SJ, Gao T, Li H, Kim MJ, Lee TH: In vitro Anti-hypertensive, Antioxidant and Anticoagulant Activities of Extracts from Haliotis discus hannai. Journal of The Korean Society of Food Science and Nutrition. 2006, 35 (7): 835-840. 10.3746/jkfn.2006.35.7.835. KoreanCrossRef
6.
Khan N, Afaq F, Mukhtar H: Cancer Chemoprevention Through Dietary Antioxidants: Progress and Promise. Antioxidants & Redox Signaling. 2008, 10 (3): 475-510.CrossRef
7.
Uchida H, Sasaki T, Uchida NA, Takasuka N, Endo Y, Kamiya H: Oncostatic and immunomodulatory effects of a glycoprotein fraction from water extract of abalone, Haliotis discus hannai. Cancer Immunology, Immunotherapy. 1987, 24 (3): 207-212. 10.1007/BF00205631.CrossRefPubMed
8.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
9.
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996, 14 (8): 2197-2205.PubMed
10.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001, 344 (11): 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
11.
Gonzalez CA: Nutrition and cancer: the current epidemiological evidence. British Journal of Nutrition. 2006, 96 (S1): S42-S45.CrossRefPubMed
12.
13.
Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E: Combined Therapy of Local and Metastatic 4T1 Breast Tumor in Mice Using SU6668, an Inhibitor of Angiogenic Receptor Tyrosine Kinases, and the Immunostimulator B7.2-IgG Fusion Protein. Cancer Res. 2002, 62 (20): 5727-5735.PubMed
14.
Pulaski BA, Ostrand-Rosenberg S: Reduction of Established Spontaneous Mammary Carcinoma Metastases following Immunotherapy with Major Histocompatibility Complex Class II and B7.1 Cell-based Tumor Vaccines. Cancer Res. 1998, 58 (7): 1486-1493.PubMed
15.
Ho-Keun K, Won Kyung J, Ji-Sun H, Choong-Gu L, Jae-Seon S, Jin AP, Byoung Seob K, Sin-Hyeog I: Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells. Cancer letters. 2009, 278 (2): 174-182. 10.1016/j.canlet.2009.01.015.CrossRef
16.
Usharauli D, Perez-Diez A, Matzinger P: The JAM Test and its daughter P-JAM: simple tests of DNA fragmentation to measure cell death and stasis. Nat Protocols. 2006, 1 (2): 672-682. 10.1038/nprot.2006.107.CrossRefPubMed
17.
Baruch K, Moshe S, Abraham K, Marianne S, Dany B, Eliezer R, David G: Splenomegaly and solitary spleen metastasis in solid tumors. Cancer. 1987, 60 (1): 100-102. 10.1002/1097-0142(19870701)60:1<100::AID-CNCR2820600118>3.0.CO;2-9.CrossRef
18.
duPre SA, Hunter JKW: Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: Association with tumor-derived growth factors. Experimental and Molecular Pathology. 2007, 82 (1): 12-24. 10.1016/j.yexmp.2006.06.007.CrossRefPubMed
19.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410 (6824): 50-56. 10.1038/35065016.CrossRefPubMed
20.
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007, 446 (7137): 765-770. 10.1038/nature05760.CrossRefPubMed
21.
Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J, Xu M, Briest S, Biragyn A: Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells. Cancer Res. 2009, 69 (14): 5996-6004. 10.1158/0008-5472.CAN-08-4619.CrossRefPubMedPubMedCentral
22.
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer. Cancer Res. 2002, 62 (3): 632-635.PubMed
23.
Neil JR, Johnson KM, Nemenoff RA, Schiemann WP: Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis. 2008, 29 (11): 2227-2235. 10.1093/carcin/bgn202.CrossRefPubMedPubMedCentral
24.
Ghosh N, Chaki R, Mandal V, Mandal SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010, 62 (2): 233-244.CrossRefPubMed
25.
Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3 (6): 401-410. 10.1038/nrc1093.CrossRefPubMed
26.
Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A: COX-2 involvement in breast cancer metastasis to bone. Oncogene. 2007, 26 (26): 3789-3796. 10.1038/sj.onc.1210154.CrossRefPubMed
27.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature. 2005, 436 (7050): 518-524. 10.1038/nature03799.CrossRefPubMedPubMedCentral
28.
Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y: Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognosis of invasive breast cancer. BMC Cancer. 2008, 8 (1): 83-10.1186/1471-2407-8-83.CrossRefPubMedPubMedCentral
29.
Larkins T, Nowell M, Singh S, Sanford G: Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006, 6 (1): 181-10.1186/1471-2407-6-181.CrossRefPubMedPubMedCentral
30.
Lake RA, Robinson BWS: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer. 2005, 5 (5): 397-405. 10.1038/nrc1613.CrossRefPubMed
31.
Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002, 2 (10): 735-747. 10.1038/nri911.CrossRefPubMed
32.
Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004, 4 (1): 11-22. 10.1038/nrc1252.CrossRefPubMed
33.
Glimcher LH, Townsend MJ, Sullivan BM, Lord GM: Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol. 2004, 4 (11): 900-911. 10.1038/nri1490.CrossRefPubMed
34.
Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. The Lancet Oncology. 2003, 4 (10): 605-615. 10.1016/S1470-2045(03)01220-8.CrossRefPubMed
35.
Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y, Nagawa H: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. British Journal of Cancer. 2000, 83 (3): 324-328. 10.1054/bjoc.2000.1270.CrossRefPubMedPubMedCentral
36.
Schneider BP, Miller KD: Angiogenesis of Breast Cancer. J Clin Oncol. 2005, 23 (8): 1782-1790. 10.1200/JCO.2005.12.017.CrossRefPubMed
37.
Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL: Cyclooxygenase-2 Inhibition by Celecoxib Reduces Proliferation and Induces Apoptosis in Angiogenic Endothelial Cells in Vivo. Cancer Res. 2002, 62 (3): 625-631.PubMed
38.
Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005, 5 (4): 263-274. 10.1038/nrc1586.CrossRefPubMed
39.
Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb RR, Böcker W, Kiesel L: Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. Journal of Cancer Research and Clinical Oncology. 2003, 129 (7): 375-382. 10.1007/s00432-003-0459-1.CrossRefPubMed
40.
41.
Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J: A novel orthotopic model of breast cancer metastasis to bone. Clinical and Experimental Metastasis. 1999, 17 (2): 163-170. 10.1023/A:1006689719505.CrossRefPubMed
42.
Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, Bouchier-Hayes DJ: Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer. 2002, 87 (2): 231-237. 10.1038/sj.bjc.6600462.CrossRefPubMedPubMedCentral
43.
Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002, 55 (6): 429-434.CrossRefPubMedPubMedCentral
44.
Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009, 30 (3): 377-386. 10.1093/carcin/bgp014.CrossRefPubMed
45.
46.
Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A: Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. Cancer Res. 2004, 64 (8): 2865-2873. 10.1158/0008-5472.CAN-03-3066.CrossRefPubMed
47.
Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB: CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis. J Immunol. 2001, 167 (9): 5042-5051.CrossRefPubMed
48.
Van Den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens JL: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clinical & Experimental Immunology. 1997, 109 (3): 501-509.CrossRef
49.
Nakagomi H: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. International Journal of Cancer. 1995, 63 (3): 366-371. 10.1002/ijc.2910630311.CrossRefPubMed
Metadata
Title
Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity
Authors
Choong-Gu Lee
Ho-Keun Kwon
Jae Ha Ryu
Sung Jin Kang
Chang-Rok Im
Jae II Kim
Sin-Hyeog Im
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2010
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-10-60

Other articles of this Issue 1/2010

BMC Complementary Medicine and Therapies 1/2010 Go to the issue

Research article

Antiproliferative effect of Tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines

Research article

Echinacea-induced cytosolic Ca2+ elevation in HEK293

Research article

The effect of Neuragen PN® on Neuropathic pain: A randomized, double blind, placebo controlled clinical trial

Research article

A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial

Research article

Antibacterial activity of traditional medicinal plants used by Haudenosaunee peoples of New York State

Research article

Antibacterial properties of tualang honey and its effect in burn wound management: a comparative study